92 related articles for article (PubMed ID: 19438240)
21. Contribution of the C1A and C1B domains to the membrane interaction of protein kinase C.
Giorgione J; Hysell M; Harvey DF; Newton AC
Biochemistry; 2003 Sep; 42(38):11194-202. PubMed ID: 14503869
[TBL] [Abstract][Full Text] [Related]
22. Characterization of AJH-836, a diacylglycerol-lactone with selectivity for novel PKC isozymes.
Cooke M; Zhou X; Casado-Medrano V; Lopez-Haber C; Baker MJ; Garg R; Ann J; Lee J; Blumberg PM; Kazanietz MG
J Biol Chem; 2018 Jun; 293(22):8330-8341. PubMed ID: 29636415
[TBL] [Abstract][Full Text] [Related]
23. Elucidating the interaction of γ-hydroxymethyl-γ-butyrolactone substituents with model membranes and protein kinase C-C1 domains.
Borah R; Mamidi N; Panda S; Gorai S; Pathak SK; Manna D
Mol Biosyst; 2015 May; 11(5):1389-99. PubMed ID: 25820877
[TBL] [Abstract][Full Text] [Related]
24. C1 Domain-targeted isophthalate derivatives induce cell elongation and cell cycle arrest in HeLa cells.
Talman V; Tuominen RK; Boije af Gennäs G; Yli-Kauhaluoma J; Ekokoski E
PLoS One; 2011; 6(5):e20053. PubMed ID: 21629792
[TBL] [Abstract][Full Text] [Related]
25. 4-benzimidazolyl-3-phenylbutanoic acids as novel PIF-pocket-targeting allosteric inhibitors of protein kinase PKCζ.
Fröhner W; Lopez-Garcia LA; Neimanis S; Weber N; Navratil J; Maurer F; Stroba A; Zhang H; Biondi RM; Engel M
J Med Chem; 2011 Oct; 54(19):6714-23. PubMed ID: 21863889
[TBL] [Abstract][Full Text] [Related]
26. Interaction of the novel anthracycline antitumor agent N-benzyladriamycin-14-valerate with the C1-regulatory domain of protein kinase C: structural requirements, isoform specificity, and correlation with drug cytotoxicity.
Roaten JB; Kazanietz MG; Caloca MJ; Bertics PJ; Lothstein L; Parrill AL; Israel M; Sweatman TW
Mol Cancer Ther; 2002 May; 1(7):483-92. PubMed ID: 12479266
[TBL] [Abstract][Full Text] [Related]
27. Evaluation of series of isobenzofuranone dimers as PKCalpha ligands: implication for the distance between the two ligand binding sites.
Baba Y; Mayumi S; Hirai G; Kawasaki H; Ogoshi Y; Yanagisawa T; Hashimoto Y; Sodeoka M
Bioorg Med Chem Lett; 2004 Jun; 14(11):2969-72. PubMed ID: 15125970
[TBL] [Abstract][Full Text] [Related]
28. Protein kinase C inhibitors: a patent review (2010 - present).
Sobhia ME; Grewal BK; Paul ML; Patel J; Kaur A; Haokip T; Kokkula A
Expert Opin Ther Pat; 2013 Nov; 23(11):1451-68. PubMed ID: 23795866
[TBL] [Abstract][Full Text] [Related]
29. Design and synthesis of protein kinase Cα activators based on 'out of pocket' interactions.
Hirai G; Ohkubo M; Tamura Y; Sodeoka M
Bioorg Med Chem Lett; 2011 Jun; 21(12):3587-90. PubMed ID: 21596562
[TBL] [Abstract][Full Text] [Related]
30. Molecular models of N-benzyladriamycin-14-valerate (AD 198) in complex with the phorbol ester-binding C1b domain of protein kinase C-delta.
Roaten JB; Kazanietz MG; Sweatman TW; Lothstein L; Israel M; Parrill AL
J Med Chem; 2001 Mar; 44(7):1028-34. PubMed ID: 11297449
[TBL] [Abstract][Full Text] [Related]
31. Current status and future prospects of C1 domain ligands as drug candidates.
Boije af Gennäs G; Talman V; Yli-Kauhaluoma J; Tuominen RK; Ekokoski E
Curr Top Med Chem; 2011; 11(11):1370-92. PubMed ID: 21513495
[TBL] [Abstract][Full Text] [Related]
32. Novel N-pyrimidin-4-yl-3-amino-pyrrolo [3, 4-C] pyrazole derivatives as PKC kinase inhibitors: a patent evaluation of US2015099743 (A1).
Das J
Expert Opin Ther Pat; 2016; 26(4):523-8. PubMed ID: 26593678
[TBL] [Abstract][Full Text] [Related]
33. Fluorescence-quenching screening of protein kinase C ligands with an environmentally sensitive fluorophore.
Nomura W; Ohashi N; Okuda Y; Narumi T; Ikura T; Ito N; Tamamura H
Bioconjug Chem; 2011 May; 22(5):923-30. PubMed ID: 21434694
[TBL] [Abstract][Full Text] [Related]
34. Protein Kinase A-Mediated Effects of Protein Kinase C Partial Agonist 5-(Hydroxymethyl)Isophthalate 1a3 in Colorectal Cancer Cells.
Tarvainen I; Nunn RC; Tuominen RK; Jäntti MH; Talman V
J Pharmacol Exp Ther; 2022 Jan; 380(1):54-62. PubMed ID: 34697230
[TBL] [Abstract][Full Text] [Related]
35. Design and synthesis of triarylacrylonitrile analogues of tamoxifen with improved binding selectivity to protein kinase C.
Carpenter C; Sorenson RJ; Jin Y; Klossowski S; Cierpicki T; Gnegy M; Showalter HD
Bioorg Med Chem; 2016 Nov; 24(21):5495-5504. PubMed ID: 27647375
[TBL] [Abstract][Full Text] [Related]
36. Protein kinase C (PKC) isoforms in cancer, tumor promotion and tumor suppression.
Isakov N
Semin Cancer Biol; 2018 Feb; 48():36-52. PubMed ID: 28571764
[TBL] [Abstract][Full Text] [Related]
37. Inverse Virtual Screening allows the discovery of the biological activity of natural compounds.
Lauro G; Masullo M; Piacente S; Riccio R; Bifulco G
Bioorg Med Chem; 2012 Jun; 20(11):3596-602. PubMed ID: 22537682
[TBL] [Abstract][Full Text] [Related]
38. Membrane Interaction and Protein Kinase C-C1 Domain Binding Properties of 4-Hydroxy-3-(hydroxymethyl) Phenyl Ester Analogues.
Talukdar D; Panda S; Borah R; Manna D
J Phys Chem B; 2014 Jul; 118(27):7541-7553. PubMed ID: 24936745
[TBL] [Abstract][Full Text] [Related]
39. Expanding the Paradigm of Structure-Based Drug Design: Molecular Dynamics Simulations Support the Development of New Pyridine-Based Protein Kinase C-Targeted Agonists.
Lautala S; Provenzani R; Tarvainen I; Sirna K; Karhu ST; Grazhdankin E; Lehtinen AK; Sa'd H; Koivuniemi A; Xhaard H; Tuominen RK; Talman V; Bunker A; Yli-Kauhaluoma J
J Med Chem; 2023 Apr; 66(7):4588-4602. PubMed ID: 37010933
[TBL] [Abstract][Full Text] [Related]
40. Probing the membrane targeting C1 subdomains of PKC with bivalent ligands.
Nowak I
Curr Top Med Chem; 2007; 7(4):355-62. PubMed ID: 17305577
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
